Atrium Therapeutics

Company snapshot

Atrium Therapeutics, Inc.’s mission is to pioneer the delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. Our proprietary technology leverages the targeted RNA delivery platform initially developed at Avidity Biosciences, Inc., which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted

• 31 active pipeline program(s) linked via ClinicalTrials.gov.
• 37 US patent(s) indexed to this assignee profile.
• 31 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Atrium Therapeutics. Not investment advice.

• Peer + 0 momentum

  Alaunos Therapeutics

  TA overlap score 26.8

• Peer + 0 momentum

  Xijing Hospital

  TA overlap score 20.8

Recent activity

Latest pipeline, patent, and corporate events for Atrium Therapeutics.

1. Jun 8, 2026 Clinical update

   Rivastigmine — Approved

2. Jun 8, 2026 Clinical update

   Phenoxybenzamine — Approved

3. Jun 8, 2026 Clinical update

   Novel Supplement Based Therapy — Phase 1

4. Jun 8, 2026 Clinical update

   Metformin Hydrochloride ER — Phase 2

5. Jun 8, 2026 Clinical update

   High Dose Vitamin D — Unknown

View all clinical trial activity →

• What is Atrium Therapeutics?

  Atrium Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker RNA. Primary therapeutic focus areas include Melanoma, Multiple Myeloma, Germ Cell Tumor, Renal Carcinoma, Acute Anterior Myocardial Infarction. NovaPharmaNews links 31 cl

• Is Atrium Therapeutics publicly traded?

  Yes. Atrium Therapeutics is listed with ticker RNA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Atrium Therapeutics develop or market?

  We link 33 drug profile(s) where Atrium Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/atrium-therapeutics#company-drugs.

• What are the latest developments for Atrium Therapeutics?

  In the last 12 months our linked public records show 31 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Atrium Therapeutics focus on?

  Atrium Therapeutics focuses on Melanoma, Multiple Myeloma, Germ Cell Tumor based on our analysis of their pipeline programs and drug development activities.